Research and development of vaccines and medicines; research and development of technology for biotechnology; development of biotechnology; research relating to biotechnology; laboratory research in the field of biology; biological research services; development of new technologies in the field of biologics; drug discovery services; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; research in the field of pharmacogenetics; development of pharmaceutical preparations and medicines; laboratory research in the field of pharmaceuticals; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs; pharmaceutical drug development services; pharmaceutical research and development; research relating to pharmaceuticals; scientific research in the field of pharmacy; medical laboratory services; research relating to new technologies for medical treatment; medical research laboratory services; scientific research for medical purposes in the area of cancerous diseases; research and development of new technologies for others in the field of amino acid for medical purpose; research and development of new technologies for others in the field of peptide for medical purposes; research and development of technology for medicinal chemical manufacturing; medicine research; scientific research relating to medical substances; medical research; scientific research relating to chemistry

Class [005]
Pharmaceutical Products

Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; cardiovascular treatment preparations; pharmaceutical preparations for the prevention of disorders of the nervous system; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; antibacterial pharmaceuticals; pharmaceutical drugs being pharmaceutical preparations namely, for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; synthetic peptides for pharmaceutical purposes namely, for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; pharmaceutical compositions for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; clinical medical reagents; clinical diagnostic reagents for medicinal use; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for use in tissue transplantation; tissue-regenerative pharmaceutical preparations; pharmaceutical preparations for tumor treatment; stimulants for the central nervous system; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for treating respiratory diseases

Mark Details

Serial Number

No 79321390

Mark Type

No Service Mark

Attorney Docket Number

No 39960-00070

44D Filed

44D Current

44E filed

44E Current

66A Filed

Yes

66A Current

Yes

Current Basis

No Basis

Legal History

Status Date	Action Taken
30^th Jan 2024	FINAL DECISION TRANSACTION PROCESSED BY IB
10^th Jan 2024	FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10^th Jan 2024	FINAL DISPOSITION PROCESSED
10^th Jan 2024	FINAL DISPOSITION NOTICE SENT TO IB
10^th Oct 2023	REGISTERED-PRINCIPAL REGISTER
10^th Oct 2023	NOTICE OF REGISTRATION CONFIRMATION EMAILED
31^st Aug 2023	EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
20^th Mar 2023	NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
17^th Mar 2023	EXTENSION OF TIME TO OPPOSE RECEIVED
01^st Mar 2023	NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

UNISTAC

Classification Information

Class [042]Computer & Software Services & Scientific Services

Class [005]Pharmaceutical Products